腹主动脉瘤开放与腔内修复偏好(PROVE-AAA)试验设计
PROVE-AAA是一项整群随机试验,旨在检验决策辅助工具能否使腹主动脉瘤患者的治疗偏好与实际接受的修复方式更好匹配。
要点
- EVAR围术期并发症和死亡率低于开放修复,但开放修复远期瘤相关并发症更少。
- 决策辅助工具可能改善患者偏好与腹主动脉瘤修复方式的一致性。
- 研究将识别影响患者选择EVAR或开放修复的因素。
核心结论
- 该试验旨在检验决策辅助工具能否使腹主动脉瘤患者的治疗偏好与实际修复方式更好匹配。
研究设计与样本
- 整群随机试验,纳入适合开放或腔内修复的腹主动脉瘤患者,来自20个VA医疗中心及其血管外科团队。
主要发现
- 随机试验发现EVAR与较低的围术期并发症和死亡率相关,而开放修复远期瘤相关并发症更少。
- EVAR和开放修复术后两年内生存率相似,且开放修复不需要密集监测。
- 初步工作提示重视较低远期并发症风险的患者可能偏好开放修复。
临床怎么用
- 研究将帮助理解影响患者选择EVAR或开放修复的因素。
- 研究将评估决策辅助工具能否帮助患者更可能接受其偏好的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For patients with abdominal aortic aneurysm (AAA), randomized trials have found endovascular AAA repair (EVAR) is associated with lower perioperative morbidity and mortality than open surgical repair (OSR). However, OSR has fewer long-term aneurysm-related complications, such as endoleak or late rupture. Patients treated with EVAR and OSR have similar survival rates within two years after surgery, and OSR does not require intensive surveillance. Few have examined if patient preferences are aligned with the type of treatment they receive for their AAA. Although many assume that patients may universally prefer the less-invasive nature of EVAR, our preliminary work suggests that patients who value the lower risk of late complications may prefer OSR. In this study, called The PReferences for Open Versus Endovascular Repair of Abdominal Aortic Aneurysm (PROVE-AAA) trial, we describe a cluster-randomized trial to test if a decision aid can better align patients' preferences and their treatment type for AAA. Patients enrolled in the study are candidates for either endovascular or open repair and are followed up at VA hospitals by vascular surgery teams who regularly perform both types of repair. In Aim 1, we will determine patients' preferences for endovascular or open repair and identify domains associated with each repair type. In Aim 2, we will assess alignment between patients' preferences and the repair type elected and then compare the impact of a decision aid on this alignment between the intervention and control groups. This study will help us to accomplish two goals. First, we will better understand the factors that affect patient preference when choosing between EVAR and OSR. Second, we will better understand if a decision aid can help patients be more likely to receive the treatment strategy they prefer for their AAA. Study enrollment began on June 1, 2017. Between June 1, 2017 and November 1, 2018, we have enrolled 178 of a total goal of 240 veterans from 20 VA medical centers and their vascular surgery teams across the country. We anticipate completing enrollment in PROVE-AAA in June 2019, and study analyses will be performed thereafter.
引用
- Columbo JA, Kang R, Spangler EL, et al. Design of the PReferences for Open Versus Endovascular Repair of Abdominal Aortic Aneurysm (PROVE-AAA) Trial. Ann Vasc Surg. 2019. PMID: 31075459. doi:10.1016/j.avsg.2019.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。